AstraZeneca and MSD Report Results of Lynparza in P-III PAOLA-1 Study as 1L Maintenance Therapy for Advanced Ovarian Cancer

 AstraZeneca and MSD Report Results of Lynparza in P-III PAOLA-1 Study as 1L Maintenance Therapy for Advanced Ovarian Cancer

AstraZeneca and MSD Report Results of Lynparza in P-III PAOLA-1 Study as 1L Maintenance Therapy for Advanced Ovarian Cancer

Shots:

  • The P-III PAOLA-1 study involves assessing of Lynparza + bevacizumab vs bevacizumab as monothx. as a 1L maintenance therapy for newly diagnosed advanced FIGO Stage III-IV high grade serous or endometroid ovarian, fallopian tube, peritoneal cancer women prior treated with platinum-based CT + bevacizumab
  • The P-III PAOLA-1 study resulted in meeting its 1EPs in the intent-to-treat population i.e, improvement in PFS, increased the time women lived without disease progression, no new safety is observed
  • Lynparza is a PARP inhibitor act by blocking DNA damage response in tumors harboring HRR mutation including BRCA1/BRCA2, jointly developed and commercialized by AstraZeneca and MSD and is an approved therapy for the treatment of advanced ovarian cancer and metastatic breast cancer

Click here to­ read full press release/ article | Ref: AstraZeneca | Image: Livemint

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post